Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Malliga Iyer · NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM · 2021 · $1,004,709 — The Arachidonic acid (AA) pathway is a major biosynthetic pathway with various mediators that are targets for disease treatments. AA and other polyunsaturated fatty acids (PUFAs) are also the substrate of various oxygenases (Cox/Lox) and cytochrome P450 enzymes (P450), whose end-products include leu…
David J Erle · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2021 · $1,797,903 — PROJECT SUMMARY/ABSTRACT COVID-19, the pandemic illness caused by the novel virus SARS-CoV-2, is a serious respiratory illness that has high infectivity and a mortality rate that varies from <1% to up to 20% depending on underlying risk factors. Indeed, disease severity varies markedly based on reco…
robert a heinzen · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $381,407 — Coxiella burnetii is a ubiquitous zoonotic bacterial pathogen and the cause of human acute Q fever, a disabling influenza-like illness. Coxiella's former obligate intracellular nature significantly impeded genetic characterization of putative virulence factors. However, our seminal advance of host c…
Thomas Nutman · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $963,448 — A. Association of plasma matrix metalloproteinase and tissue inhibitors of matrix metalloproteinase levels with adverse treatment outcomes in patients with pulmonary tuberculosis Identifying biomarkers of treatment response is an urgent need in the field of tuberculosis (TB). Matrix metalloproteinas…
Luigi Notarangelo · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $1,953,817 — In FY2021, we have identified a new gene defect responsible for an X-linked combined immunodeficiency and contributed to the characterization of three other forms of inborn errors of immunity (IEI), two of which are due to newly identified gene defects. We have also expanded knowledge on the molecul…
Helen Chun-Hui Su · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $1,632,832 — These studies have been organized as part of a broader effort among multiple principal investigators in the Intramural Research Programs of NIAID, NIDCR, NCI, and NIAMS, as well as a research collaborative agreement with investigators at the American Genome Center/Uniformed Services University of th…
Daniella Schwartz · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $42,081 — In FY2021, we continued exploring the responses of T cells from patients with MIS-C, using cells from age-matched subjects with acute SARS-CoV2 infection and age-matched healthy volunteers as comparators. Immunophenotyping began in FY2021 and is ongoing. Additionally, we have collaborated with col…
Hans Ackerman · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $3,517 — This project is part of NIAID intramural basic science research response to the COVID-19 pandemic. The SARS-CoV-2 coronavirus (which causes COVID-19) enters cells through binding with angiotensin converting enzyme 2 (ACE2). It is currently unknown whether two common blood pressure medications- ACE i…
Michael Grigg · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $104,605 — Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the etiologic agent of COVID-19, emerged in 2019 as a public health emergency and global pandemic. SARS-CoV-2 is a linear, non-segmented, capped, polyadenylated positive-sense, single stranded RNA virus related to SARS-CoV and MERS-CoV, t…
Ruili Huang · NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES · 2021 · $263,527 — The Tox21 Programs federal partners include the Environmental Protection Agency (EPA), the Food and Drug Administration (FDA) and NIH, with leadership from NCATS and the National Toxicology Program (NTP) at the National Institute of Environmental Health Sciences (NIEHS). These agencies work together…
THOMAS E DEVER · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · 2021 · $1,764,583 — We study the mechanism and regulation of protein synthesis in eukaryotic cells. Of special interest are the regulation of protein synthesis by GTP-binding (G) proteins and protein phosphorylation. In addition, we are studying unusual post-translational modifications of the factors that assist the ri…
Janet Hall · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · 2021 · $233,210 — The Environmental Polymorphisms Registry (EPR), now called Personalized Environment and Genes Study (PEGS) of over 17,000 participants provides a unique resource for a variety of studies dedicated to clarifying the interaction of genetic and environmental determinants of human health. The PEGS's sub…
Sonja Best · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $162,424 — The SARS-CoV-2 global pandemic has a continuing demand for greater understanding of the mechanisms of disease and the development of therapeutics to complement success in vaccination. These efforts were initially hampered by the fact that the most useful experimental model in these efforts, the mous…
Adrian McDermott · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2021 · $8,027,794 — The Vaccine Immunology Program (formerly NIAID Vaccine Immune T cell and Antibody Laboratory Core/Immunology Core Laboratory) is responsible for the end point analyses of clinical vaccine, therapeutic and prevention trials carried out by the Vaccine Research Center and collaborates with intramural a…
Philip Anfinrud · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · 2021 · $540,564 — The Covid-19 pandemic proved quite disruptive to these efforts. In March 2020, when faced with the prospect of being locked out of the NIH around the start of the pandemic, Dr. Ad Bax encouraged me to collaborate with him on a project to visualize speech droplets with laser light and evaluate their …
Frank Maldarelli · DIVISION OF BASIC SCIENCES - NCI · 2021 · $634,967 — Fundamental gaps in our understanding of HIV reservoirs preclude a precisely targeted approach to eradication. HIV is neither eliminated nor often controlled by the human immune system, and the immunologic defect(s) responsible for this lack of control are unknown. We are conducting several studies …
Alex Compton · DIVISION OF BASIC SCIENCES - NCI · 2021 · $216,185 — This project was initiated in spring of 2020 and is now ready for the virus challenge stage. We have obtained CRISPR-Cas9 libraries from Juan Bonifacino that can be delivered to diverse cell types by lentiviral vectors. Scarlett Shi, a Research Fellow in the lab, is leading the work on this project.…
David J Erle · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2021 · $81,105 — PROJECT SUMMARY/ABSTRACT COVID-19, the pandemic illness caused by the novel virus SARS-CoV-2, is a serious respiratory illness that has high infectivity and a mortality rate that varies from <1% to up to 20% depending on underlying risk factors. Indeed, disease severity varies markedly based on reco…
THOMAS DENNY · DUKE UNIVERSITY · 2021 · $641,460 — The purpose of the NIAID Virology Quality Assurance (VQA) program is to provide a comprehensive quality assessment program for virologic assays for HIV, and other viral pathogens, performed on samples from subjects enrolled in NIAID-sponsored multisite clinical studies. The VQA program ensures the v…
KARLA SATCHELL · NORTHWESTERN UNIVERSITY AT CHICAGO · 2021 · $307,531 — The goal of the Structural Genomics Centers for Infectious Diseases is to apply state-of-the-art, high-throughput structural biology technologies to experimentally characterize the three-dimensional atomic structure of targeted proteins on the NIAID Category A-C priority pathogens list and organisms…